trending Market Intelligence /marketintelligence/en/news-insights/trending/yiz9vkv5yqcdsf8mr1f2_g2 content esgSubNav
In This List

AstraZeneca appoints lung cancer specialist Tony Mok to board

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


AstraZeneca appoints lung cancer specialist Tony Mok to board

AstraZeneca PLC appointed Tony Mok to be a nonexecutive director and a member of its science committee, effective Jan. 1, 2019.

Mok is chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong. He is also a nonexecutive director at Hutchison China MediTech Ltd. and a co-founder and the chairman of Sanomics Ltd.

Mok is chair of the International Affair Committee and member of publication committee of ASCO, the American Society of Clinical Oncology.

He has headed multiple international phase 3 trials in lung cancer, his main research interest.

The U.K. drugmaker also confirmed the previously announced retirement of Shriti Vadera, effective Dec. 31.